Meeting
2013 ASCO Annual Meeting
A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors.
Authors
Andrew DJ Pearson
Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom
Andrew DJ Pearson , Sara Michele Federico , Isabelle Aerts , Darren R Hargrave , Steven G. DuBois , Robert Iannone , Ryan Geschwindt , Ruixue Wang , Tanya M. Trippett , Birgit Geoerger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01431547
Citation
J Clin Oncol 31, 2013 (suppl; abstr 10027)
DOI
10.1200/jco.2013.31.15_suppl.10027
Abstract #
10027
Poster Bd #
36B
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu
Poster
2016 ASCO Annual Meeting
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
First Author: Alex A. Adjei
Poster
2015 ASCO Annual Meeting
A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2013 ASCO Annual Meeting
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro